Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab

Sponsor
Centre Leon Berard
Study ID
NCT01405430
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab + blood samples — BIOLOGICAL
    Bevacizumab will be administered according to investigators appreciation. Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.

Study Details

It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response. Biological factors will be correlated to clinical outcome measures. 100 patients treated with bevacizumab for a metastatic colorectal adenocarcinoma will be enrolled. Patients will be followed every 10 weeks until progression in spite of bevacizumab or until they stop bevacizumab because of toxicity. Bevacizumab will be administered according to investigators appreciation. Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.

Key Dates

First listed
Jul 29, 2011
Start date
May 31, 2010
Status verified
Jun 2015
Primary completion
May 31, 2014
Completion
May 31, 2014

Study Design

Enrollment
63 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Experimental: Bevacizumab + blood samples

Primary Outcome Measure

Response rate to treatment [ Time Frame: Up to 1 year at most ]

Related Studies